Rich Pharmaceuticals contracts oncology clinical study to CMIC ASIA-PACIFIC
Rich Pharmaceuticals emphasizes innovative oncological therapies in its work to develop and commercialize drugs, while CMIC is one of the top CROs for clinical oncology studies in Asia.
The recently announced study will look at the treatment of Acute Myelocytic Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients.
"We are very pleased to have retained the services of a well respected and internationally recognized CRO which specializes in managing clinical studies," Rich Pharmaceuticals CEO Ben Chang said. "After carefully evaluating many competing organizations, we have chosen this CRO based on their extensive experience in managing global clinical trials of medicines."